Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties
- 1 February 2003
- journal article
- clinical trial
- Published by Elsevier BV in Contraception
- Vol. 67 (2), 93-99
- https://doi.org/10.1016/s0010-7824(02)00473-0
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Clinical comparison of triphasic norgestimate/35 μg ethinyl estradiol and monophasic norethindrone acetate/20 μg ethinyl estradiol: Cycle control, lipid effects, and user satisfactionContraception, 1999
- Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: A randomized, placebo-controlled trialObstetrics & Gynecology, 1997
- Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulationContraception, 1992
- Metabolism of norgestimate by human gastrointestinal mucosa and liver microsomes in vitroThe Journal of Steroid Biochemistry and Molecular Biology, 1991
- Relative binding affinity of norgestimate and other progestins for human sex hormone-binding globulinSteroids, 1990
- A comparison of the potencies and activities of progestogens used in contraceptivesContraception, 1987
- The affinity of norgestimate for uterine progestogen receptors and its direct action on the uterusContraception, 1985
- Distribution and percentages of non-protein bound contraceptive steroids in human serumJournal of Steroid Biochemistry, 1982
- SEX HORMONE BINDING GLOBULIN CAPACITY AS AN INDEX OF OESTROGENICITY OR ANDROGENICITY IN WOMEN ON ORAL CONTRACEPTIVE STEROIDSClinical Endocrinology, 1979
- SEX‐HORMONE‐BINDING GLOBULINClinical Endocrinology, 1974